BioWorld

April 16, 2008

Roche Buying Privately Held Piramed for $160M Up Front

Less than five years after its founding, privately held Piramed Ltd. agreed to be acquired by Roche Holdings Ltd. for $160 million up front in one of the few recent deals to stand out in the slumping UK biotech sector. (BioWorld Today) Read More

Genentech, Biogen Idec's Rituxan Misses Lofty Mark in MS Trial

At AACR, Discussions on a Faster Road to Beacons

Aileron Raises $10M to Pursue Stapled Peptides Therapeutics

Other News To Note

AACR Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...